These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26008153)

  • 21. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
    Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
    Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
    Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.
    Straver ME; Rutgers EJ; Oldenburg HS; Wesseling J; Linn SC; Russell NS; Vrancken Peeters MJ
    Am J Surg; 2009 Jul; 198(1):46-50. PubMed ID: 19095215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer.
    Straver ME; Loo CE; Alderliesten T; Rutgers EJ; Vrancken Peeters MT
    Br J Surg; 2010 Aug; 97(8):1226-31. PubMed ID: 20602508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes.
    Yegen G; Keskin M; Büyük M; Kunduz E; Balık E; Sağlam EK; Kapran Y; Asoğlu O; Güllüoğlu M
    Ann Diagn Pathol; 2016 Feb; 20():29-35. PubMed ID: 26706785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.
    He Q; Ma L; Li Y; Li G
    BMC Gastroenterol; 2016 Jan; 16():8. PubMed ID: 26782354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer.
    Chen J; Wang L; Yao Q; Ling R; Li K; Wang H
    Breast Cancer Res; 2004; 6(4):R474-7. PubMed ID: 15217515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
    Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
    J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
    Zhang J; Jiang H; Zhang J; Bao G; Zhang G; Wang H; Wang X
    BMC Cancer; 2021 Dec; 21(1):1301. PubMed ID: 34872507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Micrometastases or isolated tumor cells and the outcome of breast cancer.
    de Boer M; van Deurzen CH; van Dijck JA; Borm GF; van Diest PJ; Adang EM; Nortier JW; Rutgers EJ; Seynaeve C; Menke-Pluymers MB; Bult P; Tjan-Heijnen VC
    N Engl J Med; 2009 Aug; 361(7):653-63. PubMed ID: 19675329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
    Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: a single-institution review.
    Lee MC; Plews R; Rawal B; Kiluk JV; Loftus L; Laronga C
    Ann Surg Oncol; 2012 Jun; 19(6):1818-24. PubMed ID: 22203185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.